{"name":"Ardelyx","slug":"ardelyx","ticker":"ARDX","exchange":"NASDAQ","domain":"ardelyx.com","description":"Ardelyx, Inc. discovers, develops, and commercializes medicines to treat unmet medical needs in the United States and internationally. The company offers IBSRELA, a minimally absorbed small molecule therapy for the treatment of patients with irritable bowel syndrome with constipation; and XPHOZAH, a phosphate absorption inhibitor to reduce serum phosphorus in adults with chronic kidney disease on dialysis. Ardelyx, Inc. was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. The company was incorporated in 2007 and is headquartered in Waltham, Massachusetts.","hq":"Waltham, MA","founded":0,"employees":"489","ceo":"Mike Raab","sector":"Nephrology / Cardiorenal","stockPrice":6.12,"stockChange":0.17,"stockChangePercent":2.86,"marketCap":"$1.5B","metrics":{"revenue":2607000,"revenueGrowth":7.8,"grossMargin":72.7,"rdSpend":71527000,"netIncome":-61599000,"cash":264688992,"dividendYield":0,"peRatio":11.7,"fiscalYear":"FY2018"},"revenueBreakdown":[],"timeline":[{"date":"2019-01-01","label":"Ibsrela first approved","drug":"Ibsrela","drugSlug":"azd1722","type":"approval","sentiment":"positive"},{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2030-06-01","label":"Ibsrela patent cliff ($100M at risk)","drug":"Ibsrela","type":"patent_expiry","sentiment":"negative"},{"date":"2032-06-01","label":"Renvela patent cliff ($200M at risk)","drug":"Renvela","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":5,"colorKey":"oncology","drugs":[{"name":"AZD1722 and Midazolam","genericName":"AZD1722 and Midazolam","slug":"azd1722-and-midazolam","indication":"Other","status":"phase_1"},{"name":"AZD1722 free base tablet","genericName":"AZD1722 free base tablet","slug":"azd1722-free-base-tablet","indication":"Other","status":"phase_1"},{"name":"AZD1722 salt tablet","genericName":"AZD1722 salt tablet","slug":"azd1722-salt-tablet","indication":"Other","status":"phase_1"},{"name":"Ibsrela","genericName":"AZD1722","slug":"azd1722","indication":"Irritable bowel syndrome characterized by constipation","status":"marketed"},{"name":"Renvela","genericName":"Renvela","slug":"renvela","indication":"Renal Osteodystrophy with Hyperphosphatemia","status":"marketed"}]}],"pipeline":[{"name":"AZD1722 and Midazolam","genericName":"AZD1722 and Midazolam","slug":"azd1722-and-midazolam","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"AZD1722 free base tablet","genericName":"AZD1722 free base tablet","slug":"azd1722-free-base-tablet","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"AZD1722 salt tablet","genericName":"AZD1722 salt tablet","slug":"azd1722-salt-tablet","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Ibsrela","genericName":"AZD1722","slug":"azd1722","phase":"marketed","mechanism":"Ibsrela works by inhibiting the sodium/hydrogen exchanger 3, a protein that regulates the balance of sodium and hydrogen ions in the gut.","indications":["Irritable bowel syndrome characterized by constipation"],"catalyst":""},{"name":"Renvela","genericName":"Renvela","slug":"renvela","phase":"marketed","mechanism":"Small molecule","indications":["Renal Osteodystrophy with Hyperphosphatemia","Renal dialysis"],"catalyst":""}],"recentEvents":[{"date":"2024-02-28","type":"earnings","headline":"Ardelyx Reports Fourth Quarter and Full Year 2023 Financial Results","summary":"Ardelyx reported its financial results for the fourth quarter and full year 2023, with a net loss of $24.4 million for the year.","drugName":"","sentiment":"neutral"},{"date":"2023-11-15","type":"deal","headline":"Ardelyx Announces Collaboration with AstraZeneca to Develop AZD1722 for Nephrology Indications","summary":"Ardelyx entered into a collaboration with AstraZeneca to develop AZD1722 for nephrology indications.","drugName":"","sentiment":"positive"},{"date":"2023-08-14","type":"trial","headline":"Ardelyx Announces Positive Topline Results from Phase 2 Clinical Trial of RDX5791","summary":"Ardelyx announced positive topline results from a Phase 2 clinical trial of RDX5791.","drugName":"","sentiment":"positive"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi2AFBVV95cUxQLVhxMFI2ZndtSkF6bk01RjNpQ0Z2WGY4N21lVkk2TnRrVTNiLUk2Si1Fb2N3Wm5RS1VXQm1hdUNHMjdWV3dUVnZkWkFwVFRCTEFsekFiVUFJYnBYMVREWnVIUGV1Vl9IbFZCaEF0dnNzVkN5ZVptUWItcm9yZDJlTW9ndjhVNlB4enlNNTN6US1VdERiR2xKSE44NWEzWFNRczRBUzdRdVZsWGVWd3Z1Rm1LZkJfd0U3YU9jQ3NZZllndERCcnhidmF2dWswNUlYYjFjREVxQ1_SAd4BQVVfeXFMTnU4T2hTeXZ2VHFjdmVoMDVTM3ExWlRnUks3TnhvWGVaUnVBSzV6Z1lIMnhoQmx2c01VWlFmelJKSUNnUzlDb282NUFlSGNtd21TRnJpRTZBRnZYVUJ5dVJYamUzZi1MdnA2aTR2VUhFOHRfTkp2QUFrZzlKLXQwY2g5ZkE1d1hyNTNjWVRlbjlFY0g2Z0dyd2dOblZjZkpwdU1WSE4xZUFZQjlYYUl4LVk0bE9qamlWbUtocjItdkxaUFJtOEtkVGhIdzAyUm1sSWJSQWRXN2hablVwc0ln?oc=5","date":"2026-04-01","type":"trial","source":"simplywall.st","summary":"Assessing Ardelyx (ARDX) Valuation As New Chief Medical Officer Signals A Fresh Growth Phase - simplywall.st","headline":"Assessing Ardelyx (ARDX) Valuation As New Chief Medical Officer Signals A Fresh Growth Phase","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2026-03-14","type":"trial","source":"simplywall.st","summary":"Will Ardelyx’s (ARDX) IBSRELA Data Shift Its Competitive Position In IBS-C Treatments? - simplywall.st","headline":"Will Ardelyx’s (ARDX) IBSRELA Data Shift Its Competitive Position In IBS-C Treatments?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinwFBVV95cUxOcG9ZdTk0WmRKbm54ZkJRWEV5VVZVYl9vWl9tamtXbHZfR2V2WEZIYlRCMWtudENzZnU3TlRpeDhtemJPc18wbVF6NlR0RzYtVmdCaFRtUWhoNzhsUGtuY2dJT3doamZ6dzg0TXA5ZDdVaUhhckVfZVN0a2Z5Z1lmOWJubDIzZEV0M1AxWDUxRTdLbTdualBYSjZtS3NzMzA?oc=5","date":"2026-03-04","type":"pipeline","source":"Stock Titan","summary":"Biotech firm Ardelyx heads to Miami for back-to-back investor events - Stock Titan","headline":"Biotech firm Ardelyx heads to Miami for back-to-back investor events","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitwFBVV95cUxPRXR1WURtNk9EdUR1eGM0UXU1TnZnZnBNdUljcGcxNDVPU1J5TlBLck5BeTNqc1VTSkw4OV9YYXBoX0o4RlJPWklvdGlKREVudi1ieHZ5endLZHpWam5hVW54aEpjMng4Mk1vX09oLXpoNmVHSnBaZmNITlk4Ukh6VkRCcXZ3amJJQy1Ga1Y2djNIaU5jS3I1LUNfOGhBWHdpY1N1SHVDSU9mZDB3THdMQ3RNcXo2Mk0?oc=5","date":"2026-03-01","type":"deal","source":"The Motley Fool","summary":"Ardelyx CEO Sells 41k Shares as Company Announces Huge Partnership - The Motley Fool","headline":"Ardelyx CEO Sells 41k Shares as Company Announces Huge Partnership","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiAFBVV95cUxNNW9XOGdfeUk1ank4NDZYMmZINElTelJLVHF6aWhidE9aTzgzTzFWSW9ySW53TE5YTUZvMzNudlpjLW5XdjVraUhZNU5pVG5RM2lMbUp1OGo0WXEzQ2l4SFc0MVFfOWsxc3lzUzFaWTVTb0MtVTB5THI1YndxWEtlRTRkbG5XeFZa?oc=5","date":"2026-01-21","type":"pipeline","source":"Seeking Alpha","summary":"Ardelyx: Assessment Of Acquisition Rumors (NASDAQ:ARDX) - Seeking Alpha","headline":"Ardelyx: Assessment Of Acquisition Rumors (NASDAQ:ARDX)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixgFBVV95cUxPRjY0ZlQ4VlJLSG5zQ3Rlc3lJR0hHNFFET252NmlHNGZuQ2VsSlYtVmRyaXg5b0FlS0lMZFNUUW4yUFNWam5qZ3hfMWE0UllmTGFsblJHMkg0Y0Z6bnI1TzVFWldvX280VzFjeXZnSWZMSWw4Q0huYS1Ja05sRkJTWEJaU1V1WXZsS2Z5c0ZUR2tTcXQwbnRfSE95d1J0U0JkbGdjaWFNY3B6RmFLdlZUTE1lMll2MlVPZXJJajJVM2loeENJSGc?oc=5","date":"2026-01-20","type":"pipeline","source":"Investing.com","summary":"Ardelyx stock soars on report of potential Zydus Life acquisition - Investing.com","headline":"Ardelyx stock soars on report of potential Zydus Life acquisition","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMid0FVX3lxTE9WWC1xd2xQLXI2R20tdmdIN1ZEdWhvQnRVelBKR3pIRUFVZzlJVUh4Y0Y3OFh5NEs3d3JWUzczMk16bGZ4d1RXUF9lYUVsRkl3X3dFc3dpTExyZ1ZSdmZTTU9UejBmY2pVem80NXFMTVdYanFlZmdZ?oc=5","date":"2026-01-05","type":"pipeline","source":"Yahoo Finance","summary":"Ardelyx (ARDX) Moves 5.5% Higher: Will This Strength Last? - Yahoo Finance","headline":"Ardelyx (ARDX) Moves 5.5% Higher: Will This Strength Last?","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-12-13","type":"earnings","source":"simplywall.st","summary":"Ardelyx, Inc.'s (NASDAQ:ARDX) Path To Profitability - simplywall.st","headline":"Ardelyx, Inc.'s (NASDAQ:ARDX) Path To Profitability","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMigwFBVV95cUxPb3dPeUp1am5oV1ZnR2o4Q3lnUnJvOWRYVXg2SDkxc1QwdGR1cDFWdGVyNmd6M0UtbFJuMVc5ZWwyMFJiU0NDR0RCcnc0SllaU3NsLUM3ZkhoRzhzRVNwdHU3ZzFWeEdiR3hzcFJMamdTSHMta0VTMnZVS2gtaGFsR1Rkcw?oc=5","date":"2025-10-30","type":"earnings","source":"Yahoo Finance","summary":"Ardelyx (ARDX) Reports Break-Even Earnings for Q3 - Yahoo Finance","headline":"Ardelyx (ARDX) Reports Break-Even Earnings for Q3","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijgFBVV95cUxPZ3dMLWhSTEMwNkphN0NsZU10WDExeDBOem9DdjVMaXk4OW5ZSUhnakVHLV9ScG5PcUc5d1ZoS0RvXzFpUjlJVUc1SlhTRnl6Nzk5WC1KXzl1dHdrbjhIZ2UzZXhaWS1ZUUFJME9VZTR2bEk3ZllzVVpQTS1QWXc3c0tiSHB0SXh2dk1fLWtB?oc=5","date":"2025-10-13","type":"pipeline","source":"Yahoo Finance","summary":"Ardelyx (ARDX): Exploring Valuation After Recent Share Price Decline - Yahoo Finance","headline":"Ardelyx (ARDX): Exploring Valuation After Recent Share Price Decline","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMizgFBVV95cUxNZnNsaXFmcXJTRS1qRlNJbFRkZktXeDJxZWxyX2xrWEVUQ1Q2ZDk1Zlc4bDctU01wSnNWM1AwaTNLcGxlcElhNVZVMHhjLWZGYVRHMlI5cmNJTXJvckhMa1VyXzlFRVNtY3BIQWlEd29NN1pZMnBtZTUyeUh1UEFORHdRNnRMcjl4VUstNEt2MHhCakRDN3RrckJtVmlDbmxnZnhrcVpBNUhhRG5qaXFSMW5zQVp3OXRyRWxnRjMzSGF5Y29LTG5yWDRPcTZPZw?oc=5","date":"2025-10-13","type":"pipeline","source":"Quiver Quantitative","summary":"Ardelyx, Inc. Appoints Sue Hohenleitner as Chief Financial Officer, Effective November 4, 2025 - Quiver Quantitative","headline":"Ardelyx, Inc. Appoints Sue Hohenleitner as Chief Financial Officer, Effective November 4, 2025","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiswFBVV95cUxNU21xZGxMLUlfbXNvUW9UVjNJY3Z5WWxDMW1PcTF1Y045U3VuQUVJcnpGU2hSc3lfVGc4V0xCcDE3ekI3V3FOSWZhZnppYXRqTl9udnYtMUd6TFZaMUdoRjB6Wk9kZk1VeDRzUER6QUZQQnd1a0s4SzNLTm9HWllXb1Q4ZFctUmlaSF9zcV91VWhUVGZvY2o2VXlCaTJkQ0VqTVMwRndsSmdyU3ZUcnVWY2oyNA?oc=5","date":"2025-07-08","type":"pipeline","source":"Seeking Alpha","summary":"Ardelyx Faces An Uphill Battle Despite Oral Arguments Set In XPHOZAH Appeal (NASDAQ:ARDX) - Seeking Alpha","headline":"Ardelyx Faces An Uphill Battle Despite Oral Arguments Set In XPHOZAH Appeal (NASDAQ:ARDX)","sentiment":"neutral"}],"patents":[{"drugName":"Ibsrela","drugSlug":"tenapanor","patentNumber":"","type":"Patent Cliff","expiryDate":"2030-06-01","territory":"US","annualRevenue":100000000},{"drugName":"Renvela","drugSlug":"lanthanum-carbonate","patentNumber":"","type":"Patent Cliff","expiryDate":"2032-06-01","territory":"US","annualRevenue":200000000}],"drugCount":5,"phaseCounts":{"phase_1":3,"marketed":2},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Relypsa","Keryx Biopharmaceuticals","Vifor Pharma"],"therapeuticFocus":["Nephrology","Cardiorenal"],"financials":{"source":"sec_edgar","revenue":2607000,"revenuePeriod":"2018-12-31","revenueHistory":[{"value":2607000,"period":"2018-12-31"},{"value":85000,"period":"2018-12-31"},{"value":172000,"period":"2018-09-30"},{"value":30000,"period":"2018-06-30"},{"value":2320000,"period":"2018-03-31"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":71527000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-61599000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":null,"cashHistory":[],"totalAssets":501604000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"ciks":null,"lastFiledAt":null},"yahoo":{"currentPrice":6.12,"previousClose":5.95,"fiftyTwoWeekHigh":8.4,"fiftyTwoWeekLow":3.21,"fiftyTwoWeekRange":"3.21 - 8.4","fiftyDayAverage":6.49,"twoHundredDayAverage":5.78,"beta":0.66,"enterpriseValue":1428363136,"forwardPE":11.7,"priceToBook":8.95,"priceToSales":3.68,"enterpriseToRevenue":3.51,"enterpriseToEbitda":-37.67,"pegRatio":0,"ebitda":-37918000,"ebitdaMargin":-9.3,"freeCashflow":6751625,"operatingCashflow":-42483000,"totalDebt":233830000,"debtToEquity":140.1,"currentRatio":4.32,"returnOnAssets":-5.5,"returnOnEquity":-36.2,"analystRating":"1.1 - Strong Buy","recommendationKey":"strong_buy","numberOfAnalysts":10,"targetMeanPrice":16.1,"targetHighPrice":19,"targetLowPrice":13,"dividendRate":0,"payoutRatio":0,"fiveYearAvgDividendYield":0,"exDividendDate":0,"insiderHeldPercent":2.9,"institutionHeldPercent":69.6,"sharesOutstanding":245247427,"floatShares":222380557,"sharesShort":21701321,"shortRatio":5.02,"shortPercentOfFloat":8.8,"epsTrailing":-0.26,"epsForward":0.52,"revenuePerShare":1.69,"bookValue":0.68,"officers":[{"age":60,"name":"Mr. Michael G. Raab","title":"President, CEO & Director"},{"age":61,"name":"Ms. Elizabeth A. Grammer Esq.","title":"General Counsel"},{"age":62,"name":"Dr. Laura A. Williams M.D., M.P.H.","title":"Chief Patient Officer & Interim Chief Medical Officer"},{"age":48,"name":"Mr. Mike  Kelliher","title":"Chief Business Officer"},{"age":55,"name":"Ms. Sue  Hohenleitner","title":"Chief Financial Officer"},{"age":51,"name":"Mr. Joseph  Reilly","title":"Senior VP of Finance & Principal Accounting Officer"},{"age":null,"name":"Dr. John  Bishop Ph.D.","title":"Chief Technical & Quality Officer"},{"age":null,"name":"Ms. Caitlin  Lowie","title":"Vice President of Corporate Communications & Investor Relations"}],"industry":"Biotechnology","irWebsite":"","website":"https://www.ardelyx.com","phone":"510 745 1700"}}